NATCO Pharma Limited (NATCOPHARM) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹805 (-0.01% day change)
Key ratios
- P/E ratio
- 10.16
- P/B ratio
- 1.89
- ROE (%)
- 15.38
- ROCE (%)
- 13.09
- Debt/Equity
- 0.08
- Dividend yield (%)
- 0.52
- Market cap (₹ Cr)
- 15,791.52
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 13.45 · Beneish M-Score: -1.97
InvestSights quality score
71.7/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q1 FY27)
AI summary: The central signal is that NATCO is attempting to replace volatile Lenalidomide-led earnings with a broader base spanning India, Brazil, Canada, South Africa and Crop Health. Q1 revenue fell to ₹794.4 crores, but EBITDA margin reached 30.9%, domestic formulations delivered ₹136 crores, and Brazil grew 180% to ₹178 crores. Adcock materially supported PAT, although its quarter…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.